Clinical trial

Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer

NCT01896050

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention anastrozole, letrozole, exemestane Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Tamoxifen Normalized identity: tamoxifenView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2009-09-01

PhaseN/A

Conditions

Breast Cancerverified · MONDO: breast cancer

Arthralgiaunresolved

Obesityverified · MONDO: obesity disorder

Interventions

anastrozole, letrozole, exemestaneDRUG

TamoxifenDRUG · verified · RxNorm: tamoxifen

Sponsors & collaborators

University of Michigan Rogel Cancer Centerlead sponsor

Mapped research locations

Ann ArborMichigan, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01896050 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.